EHA 2022 | Where are we with CAR-T in CLL?
John Gribben
• 9 Jun 2022
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, talks on the current status of CAR-T therapy in chronic lymphocytic leukemia (CLL). T-cell dysfunction is a major barrier to developing CAR-T therapy for CLL. However, the introduction of ibrutinib has shown to have a great impact on the efficacy of CAR-Ts. Prof. Gribben shares his excitement for the potential approval of a CAR-T product in CLL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
